$JPM Kory Kasimov is right but just too conservative on $MRNA PT. With Ph1 data ready &amp; in #Niaid hands, #DrFauci must be all supportive of trials speed and success. PT in $80-90 is street average, $76 secondary valuation is a short cover away. #NIAIDNEWS 
https://t.co/V9AdiJguQA